Learning Objectives:
1. Recognize the role of STING in ultra-rare rheumatic diseases including SAVI and COPA syndrome.
2. Describe the role of RIG-I deficiency in antiviral immunity and hemophagocytic lymphohistiocytosis.
3. Explain how disease-causing mutant proteins can be utilized in whole-genome CRISPR/Cas9 screens to identify novel therapeutic targets.
Session date:
04/06/2021 - 8:30am to 9:30am CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Jonathan Miner, M.D., Ph.D.